Prognostic significance of statin use in colorectal cancer

Medicine (United States)

Volumn 94, Issue 25, 2015, Pages e908-

  Ying, Yanping ^a   Ling, Ying ^a   Yang, Li ^a   Huang, Huiqiao ^a   Hu, Xiaohua ^a   Zhao, Cuisong ^a   Huang, Hongyan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DRUG USE; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; PROGNOSIS;

COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS;

EID: 84941253605     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000908     Document Type: Review

References (46)

1. GLOBOCAN 2008 Web site. www.globocan.iarc.fr. Accessed October 27, 2014.
2. Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-Analysis of epidemiological studies. Cancer Causes Control. 2015; 26: 65-78.
3. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2011 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2014. Available at: www.cdc.gov/uscs
4. Van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12: 575-582.
5. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumour in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009; 27: 3379-3384.
6. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008; 26: 5721-5727.
7. Kuebler JP, Wieand HS, OConnell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABPC-07. J Clin Oncol. 2007; 25: 2198-2204.
8. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-1123.
9. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
11. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010; 9: 603-621.
12. Bonovas S, Filioussi K, Flordellis CS, et al. Statins and the risk of colorectal cancer: a meta-Analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007; 25: 3462-3468.
13. Lee J, Jung KH, Park YS, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol. 2009; 64: 657-663.
14. Katz MS, Minsky BD, Saltz LB, et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2005; 62: 1363-1370.
15. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014; 32: 3177-3183.
16. Lakha F, Theodoratou E, Farrington SM, et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer. 2012; 12: 487.
17. Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011; 103: 1540-1551.
18. Siddiqui AA, Nazario H, Mahgoub A, et al. For patients with colorectal cancer, the long-Term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009; 54: 1307-1311.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264-269.
20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-Analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 2815-2834.
21. Kuang D, Chen W, Song YZ, et al. Association between the HSPA1B 1267A/G polymorphism and cancer risk: a meta-Analysis of 14 case-control studies. Asian Pac J Cancer Prev. 2014; 15: 6855-6861.
22. Guan HB, Wu L, Wu QJ, et al. Parity and pancreatic cancer risk: a dose-response meta-Analysis of epidemiologic studies. PLoS One. 2014; 9: e92738.
23. Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epidemiol. 2010; 25: 603-605.
24. Wu L, Jiang Z, Li C, et al. Prediction of heart rate variability on cardiac sudden death in heart failure patients: a systematic review. Int J Cardiol. 2014; 174: 857-860.
25. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-Analysis: multivariate approach and meta-regression. Stat Med. 2002; 21: 589-624.
26. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002; 21: 1539-1558.
27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
28. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-Analysis. Biometrics. 2000; 56: 455-463.
29. Krens LL, Simkens LH, Baas JM, et al. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One. 2014; 9: e112201.
30. Ishikawa S, Hayashi H, Kinoshita K, et al. Statins inhibit tumour progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer. 2014; 135: 2528-2536.
31. Zanders M, Van Herk-Sukel M, Haak H, et al. Statin use as a moderator of metformin effect on overall survival in colorectal cancer patients with diabetes. Eur J Cancer. 2013; 49: S308-S309.
32. Mace AG, Gantt GA, Skacel M, et al. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum. 2013; 56: 1217-1227.
33. Ma WL, Shao YY, Hsu CH, et al. Regular statin users and colorectal cancer (CRC) prognosis. J Clin Oncol. 2013; 31 (15
34. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012; 367: 1792-1802.
35. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a metaanalysis of case-control studies. Eur J Cancer Prev. 2008; 17: 259-268.
36. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007; 120: 833-843.
37. Stein EA, Corsini A, Gimpelewicz CR, et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract. 2006; 60: 1028-1034.
38. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-Analysis of large randomized clinical trials. Am J Med. 2001; 110: 716-723.
39. Liu Y, Tang W, Wang J, et al. Association between statin use and colorectal cancer risk: a meta-Analysis of 42 studies. Cancer Causes Control. 2014; 25: 237-249.
40. McAnally JA, Jung M, Mo H. Farnesyl-O-Acetylhydroquinone and geranyl-O-Acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. Cancer Lett. 2003; 202: 181-192.
41. Sleijfer S, van der Gaast A, Planting AS, et al. The potential of statins as part of anti-cancer treatment. Eur J Cancer. 2005; 41: 516-522.
42. Dimitroulakos J, Lorimer IA, Goss G. Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res. 2006; 12: 4426s-4431s.
43. Dulak J, Loboda A, Jazwa A, et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005; 12: 233-241.
44. Dulak J, Jozkowicz A. Anti-Angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005; 5: 579-594.
45. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003; 9: 10-19.
46. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-Analysis. JAMA. 2006; 295: 74-80.